Eli Lilly and Co. turned to Finnegan, Henderson, Farabow, Garrett & Dunner to stop numerous generic drug makers from muscling into the multibillion-dollar market for depression and diabetes-related pain drug Cymbalta.
Clients like Eli Lilly “look to us for important cases about maintaining their exclusivity,” said Dori Hines, who leads the litigation practice at the Washington-based firm. After a March 2011 final judgment against the named defendant in Eli Lilly and Co. v. Wockhardt Ltd., the other eight defendants in the Southern District of Indiana case settled the next month. Finnegan has “a deep bench in terms of all of the technical areas” covered by IP litigation, Hines said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
